Longitude Capital
  • ABOUT
  • TEAM
  • PORTFOLIO
  • NEWS
  • CONTACT
  • LP LOGIN
Select Page

Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)

by Seini Moimoi | Sep 26, 2023 | Portfolio News

Patients Receiving Somatus Transitions of Care Assessment Services 49% Less Likely to Experience Hospital Readmission

by Seini Moimoi | Sep 26, 2023 | Portfolio News

89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)

by Seini Moimoi | Sep 21, 2023 | Portfolio News

FDA Approves LimFlow System in Patients with Chronic Limb-Threatening Ischemia and No Suitable Endovascular or Surgical Revasucularization Options

by Seini Moimoi | Sep 12, 2023 | Portfolio News

Mirum Pharmaceuticals Announces the Appointment of Eric Bjerkholt as Chief Financial Officer

by Seini Moimoi | Sep 11, 2023 | Portfolio News

CG Oncology Announces Key Executive Appointments in Commercialization, Medical and Manufacturing Operations

by Seini Moimoi | Sep 5, 2023 | Portfolio News

Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics

by Seini Moimoi | Sep 5, 2023 | Portfolio News

Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb

by Seini Moimoi | Sep 5, 2023 | Portfolio News

CG Oncology Announces $105 Million Oversubscribed Crossover Financing to Support Continued Advancement of Clinical-Stage Bladder Cancer Pipeline

by Seini Moimoi | Aug 2, 2023 | Portfolio News

CG Oncology Announces $105 Million Oversubscribed Crossover Financing to Advance Clinical-Stage Bladder Cancer Pipeline

by Seini Moimoi | Aug 2, 2023 | Uncategorized

« Older Entries

Media Contact

Maggie Jamison

mjamison@longitudecapital.com

650-854-5700

  • Facebook
  • Twitter
  • Google
  • RSS
footer-logo

LP Login

© 2023 Longitude Capital. All rights reserved.
  • Privacy Policy
  • Disclaimer